2020-03-21| COVID-19

USFDA Approves Cepheid’s Rapid, Point-of-Care COVID-19 Test

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

This morning, California-based Cepheid announced the USFDA’s Emergency Use Authorization (EUA) for its rapid, SARS-CoV-2 detecting, real-time RT-PCR test. Named Xpert® Xpress, this molecular diagnostic test can give results within 45 minutes, which is faster than any other tests currently available. With the pandemic spreading fast in the country, the Trump administration was originally criticized for its lapse in preventive actions and the shortage of diagnostic tests. However, in the past couple of weeks, several measures including emergency FDA approval of coronavirus tests have been taken by authorities. Cepheid’s test has now become the eleventh since March 12th and thirteenth overall to bag emergency approval after big players like Roche and Thermo Fisher.

However, it is the first point-of-care coronavirus test to be approved and is designed to operate on any of Cepheid’s preinstalled automated instruments by users without any specialty training. The company says, at present, there are 23,000 GeneXpert® systems around the world with 5,000 of them in the US alone. The point-of-care nature and rapid delivery of results give Cepheid’s test the edge over others. “Today marks an important step in expanding the availability of testing and, importantly, rapid results. Point-of-care testing means that results are delivered to patients in the patient care settings, like hospitals, urgent care centers, and emergency rooms, instead of samples being sent to a laboratory. With today’s authorization, there is now an option for testing at the point of care, which enables patient access to more immediate results” said FDA Commissioner Stephen Hahn.

GeneXpert® Systems (Image Courtesy: Cepheid)

“During this time of increased demand for hospital services, Clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities. An accurate test delivered close to the patient can be transformative — and help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on healthcare facilities that need to properly allocate their respiratory isolation resources,” said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid in a statement.

“By leveraging the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and potential future variants of SARS-CoV-2, we have developed a test that provides reference lab-quality results in multiple settings where actionable treatment information is needed quickly” he added.

Related Article: Abbott’s Homemade Coronavirus Test bags FDA’s Emergency Authorization



© All rights reserved. Collaborate with us: [email protected]
Related Post
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
Tanvex BioPharma Secures Asia’s First FDA Approval for Filgrastim Biosimilar, Seizing a $403 Million Market
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top